Cargando…
Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation
BACKGROUND: Neuroinflammation occurs as a result of microglial activation in response to invading micro-organisms or other inflammatory stimuli within the central nervous system. According to our earlier findings, Krüppel-like factor 4 (Klf4), a zinc finger transcription factor, is involved in micro...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325890/ https://www.ncbi.nlm.nih.gov/pubmed/22429472 http://dx.doi.org/10.1186/1742-2094-9-57 |
_version_ | 1782229463679893504 |
---|---|
author | Kaushik, Deepak Kumar Mukhopadhyay, Rupanjan Kumawat, Kanhaiya Lal Gupta, Malvika Basu, Anirban |
author_facet | Kaushik, Deepak Kumar Mukhopadhyay, Rupanjan Kumawat, Kanhaiya Lal Gupta, Malvika Basu, Anirban |
author_sort | Kaushik, Deepak Kumar |
collection | PubMed |
description | BACKGROUND: Neuroinflammation occurs as a result of microglial activation in response to invading micro-organisms or other inflammatory stimuli within the central nervous system. According to our earlier findings, Krüppel-like factor 4 (Klf4), a zinc finger transcription factor, is involved in microglial activation and subsequent release of proinflammatory cytokines, tumor necrosis factor alpha, macrophage chemoattractant protein-1 and interleukin-6 as well as proinflammatory enzymes, inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharide-treated microglial cells. Our current study focuses on finding the molecular mechanism of the anti-inflammatory activities of honokiol in lipopolysaccharide-treated microglia with emphasis on the regulation of Klf4. METHODS: For in vitro studies, mouse microglial BV-2 cell lines as well as primary microglia were treated with 500 ng/mL lipopolysaccharide as well as 1 μM and 10 μM of honokiol. We cloned full-length Klf4 cDNA in pcDNA3.1 expression vector and transfected BV-2 cells with this construct using lipofectamine for overexpression studies. For in vivo studies, brain tissues were isolated from BALB/c mice treated with 5 mg/kg body weight of lipopolysaccharide either with or without 2.5 or 5 mg/kg body weight of honokiol. Expression of Klf4, cyclooxygenase-2, inducible nitric oxide synthase and phospho-nuclear factor-kappa B was measured using immunoblotting. We also measured the levels of cytokines, reactive oxygen species and nitric oxide in different conditions. RESULTS: Our findings suggest that honokiol can substantially downregulate the production of proinflammatory cytokines and inflammatory enzymes in lipopolysaccharide-stimulated microglia. In addition, honokiol downregulates lipopolysaccharide-induced upregulation of both Klf4 and phospho-nuclear factor-kappa B in these cells. We also found that overexpression of Klf4 in BV-2 cells suppresses the anti-inflammatory action of honokiol. CONCLUSIONS: Honokiol potentially reduces inflammation in activated microglia in a Klf4-dependent manner. |
format | Online Article Text |
id | pubmed-3325890 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-33258902012-04-14 Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation Kaushik, Deepak Kumar Mukhopadhyay, Rupanjan Kumawat, Kanhaiya Lal Gupta, Malvika Basu, Anirban J Neuroinflammation Research BACKGROUND: Neuroinflammation occurs as a result of microglial activation in response to invading micro-organisms or other inflammatory stimuli within the central nervous system. According to our earlier findings, Krüppel-like factor 4 (Klf4), a zinc finger transcription factor, is involved in microglial activation and subsequent release of proinflammatory cytokines, tumor necrosis factor alpha, macrophage chemoattractant protein-1 and interleukin-6 as well as proinflammatory enzymes, inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharide-treated microglial cells. Our current study focuses on finding the molecular mechanism of the anti-inflammatory activities of honokiol in lipopolysaccharide-treated microglia with emphasis on the regulation of Klf4. METHODS: For in vitro studies, mouse microglial BV-2 cell lines as well as primary microglia were treated with 500 ng/mL lipopolysaccharide as well as 1 μM and 10 μM of honokiol. We cloned full-length Klf4 cDNA in pcDNA3.1 expression vector and transfected BV-2 cells with this construct using lipofectamine for overexpression studies. For in vivo studies, brain tissues were isolated from BALB/c mice treated with 5 mg/kg body weight of lipopolysaccharide either with or without 2.5 or 5 mg/kg body weight of honokiol. Expression of Klf4, cyclooxygenase-2, inducible nitric oxide synthase and phospho-nuclear factor-kappa B was measured using immunoblotting. We also measured the levels of cytokines, reactive oxygen species and nitric oxide in different conditions. RESULTS: Our findings suggest that honokiol can substantially downregulate the production of proinflammatory cytokines and inflammatory enzymes in lipopolysaccharide-stimulated microglia. In addition, honokiol downregulates lipopolysaccharide-induced upregulation of both Klf4 and phospho-nuclear factor-kappa B in these cells. We also found that overexpression of Klf4 in BV-2 cells suppresses the anti-inflammatory action of honokiol. CONCLUSIONS: Honokiol potentially reduces inflammation in activated microglia in a Klf4-dependent manner. BioMed Central 2012-03-19 /pmc/articles/PMC3325890/ /pubmed/22429472 http://dx.doi.org/10.1186/1742-2094-9-57 Text en Copyright ©2012 Kaushik et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Kaushik, Deepak Kumar Mukhopadhyay, Rupanjan Kumawat, Kanhaiya Lal Gupta, Malvika Basu, Anirban Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation |
title | Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation |
title_full | Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation |
title_fullStr | Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation |
title_full_unstemmed | Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation |
title_short | Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation |
title_sort | therapeutic targeting of krüppel-like factor 4 abrogates microglial activation |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325890/ https://www.ncbi.nlm.nih.gov/pubmed/22429472 http://dx.doi.org/10.1186/1742-2094-9-57 |
work_keys_str_mv | AT kaushikdeepakkumar therapeutictargetingofkruppellikefactor4abrogatesmicroglialactivation AT mukhopadhyayrupanjan therapeutictargetingofkruppellikefactor4abrogatesmicroglialactivation AT kumawatkanhaiyalal therapeutictargetingofkruppellikefactor4abrogatesmicroglialactivation AT guptamalvika therapeutictargetingofkruppellikefactor4abrogatesmicroglialactivation AT basuanirban therapeutictargetingofkruppellikefactor4abrogatesmicroglialactivation |